01.07.15
Waltham, Mass.-based NeuroMetrix Inc. has released its pain relief device, Quell, at the 2015 International Consumer Electronics Show (CES) held Jan. 6-9 in Las Vegas, Nev.
Quell uses the company’s proprietary non-invasive neurostimulation technology to provide relief from chronic pain, particularly nerve pain such as due to diabetes and lower back problems. The wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the U.S. Food and Drug Administration for treatment of chronic pain without a prescription. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy.
CRN, an information technology news website, included Quell as one of “25 Hot Products at CES.” Interest from global retailers has been strong as the product brings a new level of benefit and relevance to the wearable technology category.
The company expects to begin taking pre-orders for Quell in March and to ship during the second quarter. Quell will initially be available exclusively through doctors’ offices and online.
“We were pleased with the response to Quell at CES. Clearly there is a need for wearable technology that makes a meaningful and clear difference in people’s lives,” said Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix.
NeuroMetrix makes wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders.
Quell uses the company’s proprietary non-invasive neurostimulation technology to provide relief from chronic pain, particularly nerve pain such as due to diabetes and lower back problems. The wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the U.S. Food and Drug Administration for treatment of chronic pain without a prescription. Users of the device will also have the option of using their smartphone to automatically track and personalize their pain therapy.
CRN, an information technology news website, included Quell as one of “25 Hot Products at CES.” Interest from global retailers has been strong as the product brings a new level of benefit and relevance to the wearable technology category.
The company expects to begin taking pre-orders for Quell in March and to ship during the second quarter. Quell will initially be available exclusively through doctors’ offices and online.
“We were pleased with the response to Quell at CES. Clearly there is a need for wearable technology that makes a meaningful and clear difference in people’s lives,” said Shai N. Gozani, M.D., Ph.D., president and CEO of NeuroMetrix.
NeuroMetrix makes wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders.